FeesSafety
Pluang+

Alignment Healthcare faces securities fraud probe over alleged EBITDA inflation and stock drop.

Market News
23 Oct 2026
GlobeNewsWire
View Source
Bearish
Alignment Healthcare faces securities fraud probe over alleged EBITDA inflation and stock drop.

Alignment Healthcare is under investigation for securities fraud after allegations that it inflated adjusted EBITDA by misclassifying expenses to boost executive pay. A whistleblower lawsuit claims $8-10 million in operating costs were wrongly capitalized, making the company appear profitable in 2024 instead of reporting a loss. This led to a 16.7% stock drop on July 8, 2026. Investors who suffered losses may have legal options and are encouraged to contact BFA Law for potential class action participation.

The news on Alignment Healthcare's securities fraud investigation provides context for health sector market activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 23, 2026 17:11 WIB: Among 150 priced health-sector US stocks, 51 rose and 90 fell. Adaptive Biotechnologies Corp (ADPT) gained 1.76% with 100% buy orders and a typical hold time of 37 days, contrasting with AstraZeneca plc (AZN) which declined 1.47% with 78% sell orders and a longer hold time of 126 days. ImmunityBio Inc. (IBRX) also fell 1.44%, held typically for just 3 days on Pluang.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
19 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App